Yu et al. (2022) found that GRB7 (growth factor receptor bound protein 7) effectively increased major resistance to MEK inhibitors via the RTK pathway in KRAS-mutated colon cancer. PLK1 (Polo-like kinase 1) is the major interacting kinase of GRB7. The combination of PLK1 and MEK inhibitors could synergistically inhibit CRC cell proliferation and induce apoptosis in vitro and in vivo. The gene discussed is MAP2K7; the disease is malignant colon neoplasm.